Astellas Pharma confirms interim analysis of Xtandi study to occur this year

|About: Astellas Pharma, Inc. ADR (ALPMY)|By:, SA News Editor

Astellas Pharma (ALPMY.PK +1.2%) corrects a translation error in its FQ1 conference call earlier, confirming that interim analysis on its Prevail study of Xtandi will actually occur this year.

The company became aware of an error in the English translation, which cited incorrect timing of the interim analysis.

Guidance has not changed.